시장보고서

상품코드

1574947

항바이러스제 병용요법 시장 : 약제유형별, 약제병용요법별, 투여경로별, 적응증별, 국가별, 지역별 - 산업 분석, 시장 규모, 시장 점유율 예측(2024-2032년)

Antiviral Combination Therapy Market, By Drug Type, By Drug Combination, By Route of Administration, By Indication, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

발행일: 2024년 10월 | 리서치사:

AnalystView Market Insights | 페이지 정보: 영문 303 Pages | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

보고서 하이라이트

항바이러스제 병용요법 시장 규모는 2023년 490억 1,921만 달러로 2024년부터 2032년까지 연평균 복합 성장률(CAGR) 6.40%로 확대

항바이러스제 병용 요법 시장 - 시장 역학

내성 바이러스 증가로 혁신적인 항바이러스제 병용 요법이 필요합니다.

바이러스 내성 증가는 항바이러스제 병용 요법 시장의 주요 촉진요인입니다. 바이러스는 시간이 지남에 따라 변하기 때문에 현재 치료법에 대한 내성을 얻고 치료 효과가 떨어질 수 있습니다. 이러한 상황에서 내성 바이러스에 더 잘 작용하는 새로운 혁신적인 치료법이 필요합니다. 서로 다른 항바이러스제물을 조합하여 사용하면 건강 관리 제공업체가 여러 가지 방법으로 바이러스를 공격할 수 있어 성공 가능성이 높아집니다. 환자는 완고한 감염에 대한 효과적인 치료법이 필요하며 이러한 병용 요법에 대한 수요가 증가하고 있습니다. 그 결과, 항바이러스제 병용 요법 시장은 이 중요한 요구를 충족시키기 위해 성장하고 있습니다.

항바이러스제 병용 요법 시장 - 주요 인사이트

우리 리서치 애널리스트의 분석에 따르면 세계 시장은 예측 기간(2024-2032년)에 약 6.40%의 연평균 복합 성장률(CAGR)로 매년 성장할 것으로 추정됩니다.

약물 유형별로 브랜드 의약품은 2023년에 가장 큰 시장 점유율을 보여줄 것으로 예상됐습니다.

약제 병용 요법별로는 2023년에는 역전사효소 억제제가 주요 약제형이었습니다.

투여 경로별로, 경구제는 2023년의 주요 약물 유형이었습니다.

적응증별로는 인간 면역 결핍 바이러스(HIV) 치료제가 2023년 주요 유형이었습니다.

지역별로는 북미가 2023년 매출을 선도했습니다.

항바이러스제 병용 요법 시장-부문 분석 :

항바이러스제 병용 요법 세계 시장은 약물 유형, 약물 병용 요법, 투여 경로, 적응증, 지역에 따라 구분됩니다.

약물의 조합으로 시장은 네 가지 범주로 나뉩니다. 주로 HIV 치료에 사용되며 바이러스 복제에 중요한 역전사 효소를 표적으로합니다. 를 변화시키고, 바이러스의 양을 감소시키고, 환자의 결과를 개선했습니다. 이 부문은 치료 효과와 환자의 어드히어런스의 양면에서 중요한 역할을 담당하고 있으며, 항바이러스제 시장에서의 우위성을 뒷받침하고 있습니다.

이 시장은 적응증별로 두 가지 범주로 분류됩니다 : 인간 면역 결핍 바이러스(HIV), 간염 및 기타 바이러스 감염입니다. 병용 요법으로 바이러스의 양을 효과적으로 줄이고 환자의 QOL 상승하고 있습니다. HIV의 박멸에 세계적으로 주력하고 혁신적인 치료법을 계속 개발하고 있는 것이, 이 부문의 우위성에 기여하고 있습니다. 치료에 대한 인식과 접근의 향상은 항바이러스제 시장에서 이 분야의 중요성을 확고하게 하고 있습니다.

항바이러스제 병용 요법 시장 - 지리적 통찰

북미의 항바이러스제 병용요법 시장은 급성장하고 있습니다. 이 성장의 배경은 바이러스 감염 증가와 더 효과적인 치료가 필요합니다. 많은 기업들이 환자의 예후를 개선하기 위한 신약 병용 요법의 개발에 주력하고 있습니다.

내성 바이러스 균주 증가도 이러한 치료법 수요를 밀어 올리고 있습니다. 병원 및 진료소가 이러한 치료법을 널리 채택함으로써 매출 증가로 이어집니다. 정부의 지원과 연구 자금도 기업의 기술 혁신을 뒷받침하고 있습니다.

항바이러스제 병용 요법 시장 - 경쟁 구도:

항바이러스제 병용 요법 시장에서는 여러 주요 기업들이 시장 점유율을 겨루고 있습니다. 길리아드 사이언시스와 아비는 효능을 높이는 혁신적인 병용 요법으로 HIV 치료를 선도하고 있습니다. Merck & Co.와 GlaxoSmithKline은 인플루엔자 및 기타 바이러스 감염에 대한 항바이러스 치료에 주력하고 있습니다. Bristol-Myers Squibb와 Johnson & Johnson은 다양한 바이러스성 질환의 치료법을 개발하고 있습니다. AstraZeneca와 Roche는 독자적인 치료법에 기여하며, Pfizer와 Novartis는 간염과 다른 질병에 대한 새로운 조합을 모색하고 있습니다. 이러한 기업은 항상 혁신적이며 환자의 결과를 개선하고 항바이러스 영역에서 제품 제공을 확대하는 것을 목표로 하고 있습니다.

소개
북미
- 개요
- 북미의 주요 제조업체
- 미국
- 캐나다
유럽
- 개요
- 유럽의 주요 제조업체
- 독일
- 이탈리아
- 영국
- 프랑스
- 러시아
- 네덜란드
- 스웨덴
- 폴란드
- 기타
아시아태평양
- 개요
- 아시아태평양의 주요 제조업체
- 인도
- 중국
- 일본
- 한국
- 호주
- 태국
- 인도네시아
- 필리핀
- 기타
라틴아메리카
- 개요
- 라틴아메리카의 주요 제조업체
- 브라질
- 멕시코
- 아르헨티나
- 콜롬비아
- 기타
중동 및 아프리카
- 개요
- 중동 및 아프리카의 주요 제조업체
- 사우디아라비아
- 아랍에미리트(UAE)
- 이스라엘
- 터키
- 알제리
- 이집트
- 기타

제12장 주요 벤더 분석 - 항바이러스제 병용 요법 업계

경쟁 대시보드
기업 프로파일
- Gilead Sciences
- AbbVie
- Merck &Co.
- GlaxoSmithKline(GSK)
- Bristol-Myers Squibb
- Johnson &Johnson
- AstraZeneca
- Roche
- Pfizer
- Novartis
- Sanofi
- Vertex Pharmaceuticals
- Hoffmann-La Roche
- Regeneron Pharmaceuticals
- Eli Lilly and Company

제13장 애널리스트의 전방위 전망

JHS 24.11.06

REPORT HIGHLIGHT

Antiviral Combination Therapy Market size was valued at USD 49,019.21 million in 2023, expanding at a CAGR of 6.40% from 2024 to 2032.

Antiviral combination therapy is a treatment approach that uses two or more antiviral drugs together to fight viral infections. This method helps improve effectiveness by targeting different parts of the virus or its life cycle, making it harder for the virus to survive and multiply. It is often used to treat diseases like HIV and hepatitis. By combining multiple drugs, this method lowers the chances of the virus developing resistance to treatment. This strategy can result in improved health for patients and help limit the spread of infections.

Antiviral Combination Therapy Market- Market Dynamics

Rising viral resistance necessitates innovative antiviral combination therapies for effectiveness.

Rising viral resistance is a key driver for the antiviral combination therapy market. As viruses change over time, they can become resistant to current treatments, making them less effective. This situation creates the need for new and innovative therapies that can work better against these resistant viruses. By using a combination of different antiviral drugs, healthcare providers can attack the virus in multiple ways, increasing the chances of success. Patients require effective treatments for stubborn infections, leading to a higher demand for these combination therapies. As a result, the market for antiviral combination therapies is growing to meet this important need.

Antiviral Combination Therapy Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 6.40% over the forecast period (2024-2032)

Based on Drug Type segmentation, Branded was predicted to show maximum market share in the year 2023

Based on Drug Combination segmentation, Reverse Transcriptase Inhibitors was the leading Drug Type in 2023

Based on Route of Administration segmentation, Oral was the leading Drug Type in 2023

Based on Indication segmentation, Human Immunodeficiency Virus (HIV), was the leading Drug Type in 2023

based on Region, North America was the leading revenue generator in 2023

Antiviral Combination Therapy Market- Segmentation Analysis:

The Global Antiviral Combination Therapy Market is segmented based on Drug Type, Drug Combination, Route of Administration, Indication, and Region.

The market is divided into four categories based on Drug Combination. DNA polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, neuraminidase inhibitors, and others. The Reverse Transcriptase Inhibitors are particularly significant. These drugs, primarily used in the treatment of HIV, target the reverse transcriptase enzyme crucial for viral replication. Their effectiveness in combination therapies has transformed HIV management, reduced viral load, and improved patient outcomes. The ongoing development of new reverse transcriptase inhibitors also highlights their prominence in addressing drug resistance and enhancing therapeutic options. This segment's critical role in both treatment efficacy and patient adherence underscores its dominance in the antiviral market.

The market is divided into two categories based on Indication: Human Immunodeficiency Virus (HIV), Hepatitis, and other viral infections. The Human Immunodeficiency Virus (HIV) segment is the most prominent. HIV treatment has advanced significantly over the years, with combination therapies effectively reducing viral loads and improving the quality of life for patients. The global focus on eradicating HIV and the ongoing development of innovative therapies contribute to this segment's dominance. Furthermore, the high prevalence of HIV, coupled with rising awareness and access to treatment, solidifies its significance in the antiviral market landscape.

Antiviral Combination Therapy Market- Geographical Insights

The antiviral combination therapy market in North America is growing rapidly. This growth is driven by an increasing number of viral infections and the need for more effective treatments. Many companies are focusing on developing new drug combinations to improve patient outcomes.

The rise of resistant viral strains also boosts demand for these therapies. Hospitals and clinics adopting these treatments more widely, leading to higher sales. Government support and research funding are helping companies innovate.

Antiviral Combination Therapy Market- Competitive Landscape:

The antiviral combination therapy market features several key players competing for market share. Gilead Sciences and AbbVie lead in HIV treatments, with innovative combinations that enhance efficacy. Merck & Co. and GlaxoSmithKline focus on antiviral therapies for influenza and other viral infections. Bristol-Myers Squibb and Johnson & Johnson are significant, developing treatments for various viral diseases. AstraZeneca and Roche contribute with their unique therapies, while Pfizer and Novartis explore new combinations for hepatitis and other conditions. these companies are constantly innovating, aiming to improve patient outcomes and expand their product offerings in the antiviral space.

Recent Developments:

In March 2024, Gilead Sciences completed its acquisition of CymaBay Therapeutics, enhancing its portfolio in the field of liver disease treatments. This strategic move aims to bolster Gilead's pipeline with CymaBay's promising therapies.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL ANTIVIRAL COMBINATION THERAPY MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Gilead Sciences
AbbVie
Merck & Co.
GlaxoSmithKline (GSK)
Bristol-Myers Squibb
Johnson & Johnson
AstraZeneca
Roche
Pfizer
Novartis
Sanofi
Vertex Pharmaceuticals
Hoffmann-La Roche
Regeneron Pharmaceuticals
Eli Lilly and Company

GLOBAL ANTIVIRAL COMBINATION THERAPY MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032

Branded
Generic

GLOBAL ANTIVIRAL COMBINATION THERAPY MARKET, BY DRUG COMBINATION- MARKET ANALYSIS, 2019 - 2032

DNA Polymerase Inhibitors
Reverse Transcriptase Inhibitors
Protease Inhibitors
Neuraminidase Inhibitors
Others

GLOBAL ANTIVIRAL COMBINATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

Oral
Intravenous

GLOBAL ANTIVIRAL COMBINATION THERAPY MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

Human Immunodeficiency Virus
Hepatitis
Others

GLOBAL ANTIVIRAL COMBINATION THERAPY MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Russia
Netherlands
Sweden
Poland
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
United Arab Emirates
Israel
Turkey
Algeria
Egypt
Rest of MEA

1. Antiviral Combination Therapy Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Antiviral Combination Therapy Market Snippet by Drug Type
- 2.1.2. Antiviral Combination Therapy Market Snippet by Drug Combination
- 2.1.3. Antiviral Combination Therapy Market Snippet by Route of Administration
- 2.1.4. Antiviral Combination Therapy Market Snippet by Indication
- 2.1.5. Antiviral Combination Therapy Market Snippet by Country
- 2.1.6. Antiviral Combination Therapy Market Snippet by Region
2.2. Competitive Insights

3. Antiviral Combination Therapy Key Market Trends

3.1. Antiviral Combination Therapy Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Antiviral Combination Therapy Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Antiviral Combination Therapy Market Opportunities
3.4. Antiviral Combination Therapy Market Future Trends

4. Antiviral Combination Therapy Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Antiviral Combination Therapy Market: COVID-19 Impact Analysis

5.1. Pre-COVID-19 Impact Analysis
5.2. Post-COVID-19 Impact Analysis
- 5.2.1. Top Performing Segments
- 5.2.2. Marginal Growth Segments
- 5.2.3. Top Looser Segments
- 5.2.4. Marginal Loss Segments

6. Antiviral Combination Therapy Market Landscape

6.1. Antiviral Combination Therapy Market Share Analysis, 2023
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Antiviral Combination Therapy Market - By Drug Type

7.1. Overview
- 7.1.1. Segment Share Analysis, By Drug Type, 2023 & 2032 (%)
- 7.1.2. Branded
- 7.1.3. Generic

8. Antiviral Combination Therapy Market - By Drug Combination

8.1. Overview
- 8.1.1. Segment Share Analysis, By Drug Combination, 2023 & 2032 (%)
- 8.1.2. DNA Polymerase Inhibitors
- 8.1.3. Reverse Transcriptase Inhibitors
- 8.1.4. Protease Inhibitors
- 8.1.5. Neuraminidase Inhibitors
- 8.1.6. Others

9. Antiviral Combination Therapy Market - By Route of Administration

9.1. Overview
- 9.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
- 9.1.2. Oral
- 9.1.3. Intravenous

10. Antiviral Combination Therapy Market - By Indication

10.1. Overview
- 10.1.1. Segment Share Analysis, By Drug Combination, 2023 & 2032 (%)
- 10.1.2. Human Immunodeficiency Virus
- 10.1.3. Hepatitis
- 10.1.4. Others

11. Antiviral Combination Therapy Market- By Geography

11.1. Introduction
- 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
11.2. North America
- 11.2.1. Overview
- 11.2.2. Antiviral Combination Therapy Key Manufacturers in North America
- 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.2.4. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 11.2.5. North America Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
- 11.2.6. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.2.7. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 11.2.8. U.S.
  - 11.2.8.1. Overview
  - 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.2.8.3. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.2.8.4. U.S. Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
  - 11.2.8.5. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.2.8.6. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 11.2.9. Canada
  - 11.2.9.1. Overview
  - 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.2.9.3. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.2.9.4. Canada Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
  - 11.2.9.5. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.2.9.6. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.3. Europe
- 11.3.1. Overview
- 11.3.2. Antiviral Combination Therapy Key Manufacturers in Europe
- 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.3.4. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 11.3.5. Europe Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
- 11.3.6. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.3.7. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 11.3.8. Germany
  - 11.3.8.1. Overview
  - 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.8.3. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.3.8.4. Germany Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
  - 11.3.8.5. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.8.6. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 11.3.9. Italy
  - 11.3.9.1. Overview
  - 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.9.3. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.3.9.4. Italy Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
  - 11.3.9.5. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.9.6. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 11.3.10. United Kingdom
  - 11.3.10.1. Overview
  - 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.10.3. United Kingdom Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.3.10.4. United Kingdom Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
  - 11.3.10.5. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.10.6. United Kingdom Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 11.3.11. France
  - 11.3.11.1. Overview
  - 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.11.3. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.3.11.4. France Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
  - 11.3.11.5. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.11.6. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 11.3.12. Russia
  - 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.12.2. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.3.12.3. Russia Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
  - 11.3.12.4. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.12.5. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 11.3.13. Netherlands
  - 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.13.2. Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.3.13.3. Netherlands Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
  - 11.3.13.4. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.13.5. Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 11.3.14. Sweden
  - 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.14.2. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.3.14.3. Sweden Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
  - 11.3.14.4. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.14.5. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 11.3.15. Poland
  - 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.15.2. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.3.15.3. Poland Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
  - 11.3.15.4. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.15.5. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 11.3.16. Rest of Europe
  - 11.3.16.1. Overview
  - 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.3.16.3. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.3.16.4. Rest of the Europe Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
  - 11.3.16.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.3.16.6. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.4. Asia Pacific (APAC)
- 11.4.1. Overview
- 11.4.2. Antiviral Combination Therapy Key Manufacturers in Asia Pacific
- 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.4.4. Asia Pacific Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 11.4.5. Asia Pacific Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
- 11.4.6. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.4.7. Asia Pacific Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 11.4.8. India
  - 11.4.8.1. Overview
  - 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.8.3. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.4.8.4. India Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
  - 11.4.8.5. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.8.6. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 11.4.9. China
  - 11.4.9.1. Overview
  - 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.9.3. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.4.9.4. China Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
  - 11.4.9.5. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.9.6. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 11.4.10. Japan
  - 11.4.10.1. Overview
  - 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.10.3. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.4.10.4. Japan Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
  - 11.4.10.5. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.10.6. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 11.4.11. South Korea
  - 11.4.11.1. Overview
  - 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.11.3. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.4.11.4. South Korea Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
  - 11.4.11.5. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.11.6. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 11.4.12. Australia
  - 11.4.12.1. Overview
  - 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.12.3. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.4.12.4. Australia Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
  - 11.4.12.5. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.12.6. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 11.4.13. Thailand
  - 11.4.13.1. Overview
  - 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.13.3. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.4.13.4. Thailand Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
  - 11.4.13.5. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.13.6. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 11.4.14. Indonesia
  - 11.4.14.1. Overview
  - 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.14.3. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.4.14.4. Indonesia Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
  - 11.4.14.5. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.14.6. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 11.4.15. Philippines
  - 11.4.15.1. Overview
  - 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.15.3. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.4.15.4. Philippines Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
  - 11.4.15.5. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.15.6. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 11.4.16. Rest of APAC
  - 11.4.16.1. Overview
  - 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.4.16.3. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.4.16.4. Rest of APAC Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
  - 11.4.16.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.4.16.6. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.5. Latin America
- 11.5.1. Overview
- 11.5.2. Antiviral Combination Therapy Key Manufacturers in Latin America
- 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.5.4. Latin America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 11.5.5. Latin America Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
- 11.5.6. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.5.7. Latin America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 11.5.8. Brazil
  - 11.5.8.1. Overview
  - 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.8.3. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.5.8.4. Brazil Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
  - 11.5.8.5. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.8.6. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 11.5.9. Mexico
  - 11.5.9.1. Overview
  - 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.9.3. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.5.9.4. Mexico Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
  - 11.5.9.5. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.9.6. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 11.5.10. Argentina
  - 11.5.10.1. Overview
  - 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.10.3. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.5.10.4. Argentina Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
  - 11.5.10.5. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.10.6. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 11.5.11. Colombia
  - 11.5.11.1. Overview
  - 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.11.3. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.5.11.4. Colombia Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
  - 11.5.11.5. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.11.6. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 11.5.12. Rest of LATAM
  - 11.5.12.1. Overview
  - 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.5.12.3. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.5.12.4. Rest of LATAM Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
  - 11.5.12.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.5.12.6. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.6. Middle East and Africa
- 11.6.1. Overview
- 11.6.2. Antiviral Combination Therapy Key Manufacturers in Middle East and Africa
- 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 11.6.4. Middle East and Africa Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
- 11.6.5. Middle East and Africa Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
- 11.6.6. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
- 11.6.7. Middle East and Africa Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 11.6.8. Saudi Arabia
  - 11.6.8.1. Overview
  - 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.8.3. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.6.8.4. Saudi Arabia Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
  - 11.6.8.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.8.6. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 11.6.9. United Arab Emirates
  - 11.6.9.1. Overview
  - 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.9.3. United Arab Emirates Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.6.9.4. United Arab Emirates Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
  - 11.6.9.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.9.6. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 11.6.10. Israel
  - 11.6.10.1. Overview
  - 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.10.3. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.6.10.4. Israel Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
  - 11.6.10.5. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.10.6. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 11.6.11. Turkey
  - 11.6.11.1. Overview
  - 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.11.3. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.6.11.4. Turkey Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
  - 11.6.11.5. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.11.6. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 11.6.12. Algeria
  - 11.6.12.1. Overview
  - 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.12.3. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.6.12.4. Algeria Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
  - 11.6.12.5. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.12.6. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 11.6.13. Egypt
  - 11.6.13.1. Overview
  - 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.13.3. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.6.13.4. Egypt Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
  - 11.6.13.5. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.13.6. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 11.6.14. Rest of MEA
  - 11.6.14.1. Overview
  - 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 11.6.14.3. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
  - 11.6.14.4. Rest of MEA Market Size and Forecast, By Drug Combination, 2019 - 2032 (US$ Million)
  - 11.6.14.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
  - 11.6.14.6. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Antiviral Combination Therapy Industry

12.1. Competitive Dashboard
12.2. Company Profiles
- 12.2.1. Gilead Sciences
- 12.2.2. AbbVie
- 12.2.3. Merck & Co.
- 12.2.4. GlaxoSmithKline (GSK)
- 12.2.5. Bristol-Myers Squibb
- 12.2.6. Johnson & Johnson
- 12.2.7. AstraZeneca
- 12.2.8. Roche
- 12.2.9. Pfizer
- 12.2.10. Novartis
- 12.2.11. Sanofi
- 12.2.12. Vertex Pharmaceuticals
- 12.2.13. Hoffmann-La Roche
- 12.2.14. Regeneron Pharmaceuticals
- 12.2.15. Eli Lilly and Company

13. 360 Degree Analyst View

14. Appendix

14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us